FDA notes heart events, tumors with Novo drug

WASHINGTON (AP) -- Federal health officials say a potential blockbuster diabetes drug from Novo Nordisk appears to work. But it says questions remain about its effect on the heart and other organs.

Results from the drugmaker show liraglutide (Leer-A'-gloo-tyde) helps control blood sugar when used alone or with other medications. But regulators have concerns about heart problems and thyroid tumors seen in some company studies.

Novo Nordisk is hoping its once-a-day injection can take sales away from Byetta, a twice-a-day injection from Eli Lilly and Amylin Pharmaceuticals that works similarly.

The FDA meets with its outside diabetes experts this week to review liraglutide and another drug looking to compete in the expanding $5.1 billion U.S. market for diabetes drugs.

(Copyright 2009 by The Associated Press. All Rights Reserved.)


Join the Conversation!

To comment, the following rules must be followed:

  • No Obscenity, Profanity, Vulgarity, Racism or Violent Descriptions
  • No Negative Community Comparisons
  • No Fighting, Name-calling, or Personal Attacks
  • Multiple Accounts are Not Allowed
  • Stay on Story Topic

Comments may be monitored for inappropriate content, but the station is under no legal obligation to do so.
If you believe a comment violates the above rules, please use the Flagging Tool to alert a Moderator.
Flagging does not guarantee removal.

Multiple violations may result in account suspension.
Decisions to suspend or unsuspend accounts are made by Station Moderators.
Links require admin approval before posting.
Questions may be sent to webmaster@wvlt-tv.com. Please provide detailed information.

powered by Disqus

WVLT VOLUNTEER TV

6450 Papermill Drive Knoxville, TN 37919 Phone - (865) 450-8888; Fax - (865) 450-8869
Copyright © 2014 WVLT-TV Inc. - Designed by Gray Digital Media - Powered by Clickability 42190822 - local8now.com/a?a=42190822
Gray Television, Inc.